The FAST UK newsletter highlights significant developments in Angelman syndrome research, including progress in gene therapy, breakthrough therapy designation for GTX-102 and updates on Phase 3 clinical trials. It also shares community fundraising achievements, awareness initiatives, upcoming scientific events and opportunities for families to get involved in supporting research and the wider Angelman community.
